Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $30.00 Consensus Price Target from Brokerages

by · The Cerbat Gem

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been given a consensus rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $30.00.

Several research firms recently commented on EYPT. Royal Bank Of Canada lifted their target price on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Mizuho set a $28.00 target price on shares of Eyepoint Pharmaceuticals in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th.

Read Our Latest Analysis on Eyepoint Pharmaceuticals

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $1,200,000. Invesco Ltd. grew its stake in Eyepoint Pharmaceuticals by 174.3% in the 1st quarter. Invesco Ltd. now owns 42,948 shares of the company’s stock valued at $233,000 after buying an additional 27,291 shares in the last quarter. American Century Companies Inc. bought a new stake in Eyepoint Pharmaceuticals during the 1st quarter valued at $232,000. Dynamic Technology Lab Private Ltd boosted its stake in Eyepoint Pharmaceuticals by 127.8% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company’s stock worth $397,000 after purchasing an additional 41,132 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Eyepoint Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock worth $20,782,000 after acquiring an additional 31,141 shares during the period. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Down 1.7%

Shares of Eyepoint Pharmaceuticals stock opened at $17.89 on Friday. The firm’s 50 day moving average is $14.56 and its 200 day moving average is $12.54. The firm has a market capitalization of $1.48 billion, a PE ratio of -5.98 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $3.33 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. As a group, research analysts anticipate that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

About Eyepoint Pharmaceuticals

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

Further Reading